Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin asset

Aardvark is set to unblind its rare disease trial after the FDA imposed a full clinical hold on its candidate. The article also discusses Alumis' verdict on the Acelyrin asset, alongside updates on Tenaya’s TN-401 and Taiho’s Inqovi. This news highlights the ongoing developments and challenges in the health biotech sector.